Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.9K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.9K
RNA Interference01:23

RNA Interference

27.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

319
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
319
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

338
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
338
Types of RNA01:23

Types of RNA

71.2K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
71.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis.

Scandinavian journal of gastroenterology·2026
Same author

Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitment.

iGIE : innovation, investigation and insights·2026
Same author

Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.

Inflammatory bowel diseases·2026
Same author

Postpartum nonsteroidal anti-inflammatory drug exposure does not increase risk for flare in patients with inflammatory bowel disease.

Annals of gastroenterology·2026
Same author

Is It Safe? Long-Term Anti-TNF Therapy - Less to Fear Than We Think.

Digestive diseases and sciences·2026
Same author

Sertraline-Associated Microscopic Colitis Flare in Pregnancy.

ACG case reports journal·2026

Related Experiment Video

Updated: Nov 29, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.0K

Endogenous antisense RNA curbs CD39 expression in Crohn's disease.

Rasika P Harshe1, Anyan Xie2, Marta Vuerich1

  • 1Department of Anesthesia, Critical Care & Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.

Nature Communications
|November 19, 2020
PubMed
Summary

A novel antisense RNA regulates CD39, an enzyme crucial for immune suppression. Increased antisense in Crohn's disease patients suggests a therapeutic target for restoring immune balance.

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

199
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

892

Related Experiment Videos

Last Updated: Nov 29, 2025

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.0K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

199
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

892

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • CD39 (an ectonucleotidase) converts nucleotides to immunosuppressive adenosine.
  • CD39 is expressed on regulatory T (Treg) and T-helper (Th) 17 cells, modulating immune responses.
  • Known CD39 regulation involves genetic variations and signaling pathways.

Purpose of the Study:

  • To investigate a novel regulatory mechanism of CD39 involving endogenous antisense RNA.
  • To assess the role of CD39-specific antisense RNA in Crohn's disease pathogenesis.
  • To explore therapeutic potential of targeting this antisense RNA.

Main Methods:

  • Analysis of CD39-specific antisense RNA levels in patient immune cells.
  • Investigation of antisense RNA localization and interaction with nuclear proteins (nucleolin, hnRNP-A1).
  • In vitro antisense silencing and in vivo colitis model in humanized mice.

Main Results:

  • A CD39-specific antisense RNA, transcribed from the gene's 3'-end, was identified.
  • Increased antisense RNA was observed in Treg and Th17 cells from Crohn's disease patients.
  • Antisense silencing led to CD39 upregulation and improved colitis symptoms in mice.

Conclusions:

  • Endogenous antisense RNA represents a new mechanism for CD39 regulation.
  • CD39-specific antisense RNA is implicated in Crohn's disease.
  • Targeting this antisense RNA could restore CD39 function and immune homeostasis in Crohn's disease.